Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
Eledon Pharmaceuticals (Nasdaq: ELDN) announced that its President and Chief Scientific Officer, Steve Perrin, Ph.D., will present at the 18th Congress of the International Xenotransplantation Association (IXA) in Geneva, Switzerland. The presentation will take place on October 1, 2025, from 10:30 a.m. to 12:00 p.m. CET during a plenary session focused on immunosuppression and anti-CD154 pathway blockade.
Eledon Pharmaceuticals (Nasdaq: ELDN) ha annunciato che il suo Presidente e Direttore Scientifico, Steve Perrin, Ph.D., presenterà al 18º Congresso dell'International Xenotransplantation Association (IXA) a Ginevra, Svizzera. La presentazione si terrà il 1 ottobre 2025, dalle 10:30 alle 12:00 CET durante una plenaria incentrata sull'immunosoppressione e sul blocco della via anti-CD154.
Eledon Pharmaceuticals (Nasdaq: ELDN) anunció que su presidente y director científico, Steve Perrin, Ph.D., presentará en el 18º Congreso de la International Xenotransplantation Association (IXA) en Ginebra, Suiza. La presentación tendrá lugar el 1 de octubre de 2025, de 10:30 a.m. a 12:00 p.m. CET durante una sesión plenaria centrada en la inmunosupresión y el bloqueo de la vía anti-CD154.
Eledon Pharmaceuticals (Nasdaq: ELDN)는 사장 겸 최고과학책임자 Steve Perrin, Ph.D.가 제네바, 스위스에서 열리는 제18회 국제 이식학회 IXA 학술대회에서 발표할 예정이라고 발표했습니다. 발표는 2025년 10월 1일 10:30~12:00 CET의 plenary 세션에서 면역억제 및 anti-CD154 경로 차단에 초점을 맞춰 진행됩니다.
Eledon Pharmaceuticals (Nasdaq : ELDN) a annoncé que son président et directeur scientifique, Steve Perrin, Ph.D., présentera au 18e Congrès de l'Association internationale de xenotransplantation (IXA) à Genève, Suisse. La présentation aura lieu le 1er octobre 2025, de 10 h 30 à 12 h 00 CET lors d'une session plénière axée sur l'immunosuppression et le blocage de la voie anti-CD154.
Eledon Pharmaceuticals (Nasdaq: ELDN) gab bekannt, dass sein Präsident und Chief Scientific Officer, Steve Perrin, Ph.D., auf dem 18. Kongress der International Xenotransplantation Association (IXA) in Genf, Schweiz, auftreten wird. Die Präsentation findet am 1. Oktober 2025, von 10:30 Uhr bis 12:00 Uhr MEZ während einer Plenarsitzung statt, die sich auf Immunsuppression und Blockade des Anti-CD154-Wegs konzentriert.
Eledon Pharmaceuticals (ناسداك: ELDN) أعلنت أن رئيسها والمدير العلمي ستيف بيرين، د.اه. سيقدم في المؤتمر الثامن عشر للجمعية الدولية للزراعة النباتية (IXA) في جنيف، سويسرا. ستعقد العرض في 1 أكتوبر 2025، من الساعة 10:30 صباحاً حتى 12:00 ظهراً بتوقيت وسط أوروبا خلال جلسة عامة تركز على التخفيض المناعي وقطع مسار anti-CD154.
Eledon Pharmaceuticals（纳斯达克代码：ELDN）宣布，其总裁兼首席科学官 Steve Perrin 博士将于在瑞士日内瓦举行的国际异种移植学会（IXA）第18届大会上发表。演讲将在 2025年10月1日，欧洲中部时间（CET）10:30–12:00 的全体会议中进行，主题为免疫抑制及 anti-CD154 路径的阻断。
- None.
- None.
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upcoming 18th Congress of the International Xenotransplantation Association (IXA) taking place from September 30–October 3, 2025, in Geneva, Switzerland.
Details are as follows:
Plenary Session: Immunosuppression, Immune Monitoring, Anti-CD154* Pathway Blockade: How Far do We Need to Go?
Lecture Title: 201.2 Anti-CD154 Pathway Blockade
Date: Wednesday, October 1, 2025
Time: 10:30 a.m. – 12:00 p.m. CET
*CD154 is also known as CD40L or CD40 Ligand
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
When is Eledon Pharmaceuticals (ELDN) presenting at the IXA Congress 2025?
Who will be presenting for Eledon Pharmaceuticals at the IXA Congress 2025?
What topic will Eledon Pharmaceuticals (ELDN) discuss at the IXA Congress 2025?
Where is the 18th Congress of the International Xenotransplantation Association being held?
